Connect with us

Emerging Markets

Livento Group (OTC Pink: NUGN) Under Accumulation as Co Becomes Profitable & Applies to List on OTCQB (Boxo, Euro-Dot, AI & Rezidence Geminos)

Published

on

Livento Group (OTC Pink: NUGN) is one penny stock with big dreams and big ideas that has been in a steady uptrend in recent months looking to take out 52-week highs of $0.20 per share. NUGN was an old pot stock that was going nowhere until Livento Group went public via a reverse merger into NUGN. Since going public Livento recently submitted the application for a change of name from NuGene International Inc. to Livento Group LLC. The Company has been informed by OTC Markets that the review process for obtaining proprietary trading under Rule 15c2-11 has begun and will reflect sometime in September along with the upgrade to OTCQB.  Upon completion of this step, management intends to retire any surplus unissued authorized shares to better reflect the value of our company. 

Livento has a lot going on; recently the Company’s subsidiary BOXO started two development projects and joined one post production project. BOXO plans to start another 3 project this autumn, these were secured during May 2022 and will be announced asap. Current movie projects are Carnival of Killers movie, which will be large studio movie, Running Wild and Wash mi in the river. Elisee is currently tested by large German fund and running live in several US fund management companies where it helps with investment decisions within selected portfolios. Elisee revenues have increased significantly over the past quarter. The Company is also evaluating setting of offices in Miami to create new positions accommodating senior financial managers for Elisee sales and social media profiles to boost Company presence in USA.  

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Livento Group (OTC Pink: NUGN) is focused on acquiring and developing companies with disruptive business models. The company recently launched BOXO Productions, its film and television production subsidiary led by top actor and producers in the industry. Livento went public via NUGN and the Company is currently in the process of changing its name to Livento Group and uplisting to fully reporting OTCQB. Livento is working on EURO DOT project where it holds 15% equity part and is preparing an IPO for the logistics Company with revenues above USD $12 million with target to deliver new acquisition and business growth under EURO DOT brand.   

The Company’s operating subsidiaries include BOXO Productions; a prominent independent film and television production company that is led by an established financial, legal and entertainment team. The Company produces and funds premium content across a range of genres, championing the boldest and most original voices in modern entertainment. BOXO put together a highly experienced management team including, Petr Jákl, Ara and Martin Barab. These are Hollywood industry professionals with a very extensive track record in Tinseltown. They have access to people (and resources) that are otherwise impossible to get. The team gets access to scripts, books, new movie projects, way ahead of anyone else.  

Livento’s AI software was developed internally so it’s the Company’s own proprietary system that’s tested on the major exchanges, the Dow Jones Industrial Average (INDEXDJX: DJI) being the main testing platform. It’s a system and tool that allows fund managers to test their portfolio setup in different sectors and environments, which helps by guiding them towards which type of stock portfolio they should be buying and holding for the upcoming future. Livento works on a monthly basis and is currently being tested by a large fund in Germany that trades on the German DAX Performance Index. The primary product; portfolio management system Elisee is an investment service that allows clients to choose from a select group of assets, and leverages the latest technologies to deliver the best-performing ones based on clients’ chosen attributes. 

The Company’s real estate Invesment the Rezidence Geminos project was recently completed, and all units are now sold. Located in Prague, Czech Republic, this building is a newly constructed 16-unit condominium. Each unit has a front garden and a terrace or balcony. The building is a modern, energy-efficient construction that has plenty of parking. In 2019, Livento acquired the project and its construction permit. They began updating this building’s layout to reflect changes in market needs. The Geminos Rezidence project was financed in cooperation with UniCredit bank and developed internally under the supervision of an experienced team who oversaw all construction tenders and sales. The total gross sales were anticipated to be $8 million, and construction was expected to be completed in 18 months. With homebuyers obtaining mortgages, Livento has been receiving payments for the units and will be able to use the remaining balance once the bank and developer are paid. The team of professionals overseeing this project was led by Michal Zelezny, a veteran in the real estate industry with experience developing residential communities. 

To Find out the inside Scoop on NUGN Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

NUGN

On July 27 Livento announced the following Shareholder Letter: 

To Our Stockholders, 2021 has brought accelerated growth for Livento Group, placing us on the fast-track to trading on the public markets with the aim of upgrading to a higher exchange. The expansion of our business model into the film and television industry and onboarding of legendary Hollywood producers, the evolution of our AI program, Elise™, into larger market sectors, the approaching completion of real estate projects, and the establishment of key partnerships with influential members of the global financial community have all served to propel Livento to new horizons in a proportionately short period of time. 

As always, we seek to increase shareholder value and surpass shareholder expectations in all our endeavors. We hold shareholder communication as a high priority in maintaining the integrity and transparency of our company. To this end, we would like to provide our shareholders with a material events line-up for the fourth quarter of 2022.  

In May 2022, BOXO Productions announced its acquisition of interest in the post-production phase of the film “Wash Me In The River” featuring Robert De Niro which was due to hit theaters this fall 2022.  The film is scheduled to be release in theaters this September 2023, and will subsequently be distributed by Paramount Home Entertainment. 

There has been considerable speculation concerning the IPO for logistics company Euro Dot, which generates over 12 million USD and will significantly boost Livento’s revenue stream upon being listed.  We expect to launch the IPO in September of 2023, following up with a number of strategic acquisitions currently being explored under the Euro Dot brand.

 

For More on NUGN Subscribe Right Now!

Currently trading at a $28 million market valuation NUGN OS is 219,001,268 with 168,486,122 shares in the public float. NUGN has a strong balance sheet with $23 million in assets and just $475,000 in liabilities with no convertible notes. The Company is making money recently reporting $951,500 in sales for Q1 and Q2 2022 with a net income of $633,668. NUGN is an exciting story developing in small caps, currently in the process of changing its name to Livento Group with a new ticker symbol and uplsting to fully reporting OTCQB. Management’s ultimate goal is to list Livento on a senior stock exchange such as Nasdaq or NYSE. Livento has a lot going on besides the upcoming name and ticker change. The Company is working on EURO DOT project where it holds 15% equity part and is preparing an IPO for the logistics Company with revenues above USD $12 million with target to deliver new acquisition and business growth under EURO DOT brand. BOXO started two development projects and joined one post production project. BOXO plans to start another 3 project this autumn. The Company’s real estate Invesment the Rezidence Geminos project was recently completed, and all 16 units are now sold. Livento is also evaluating setting of offices in Miami to create new positions accommodating senior financial managers for Elisee sales and social media profiles to boost Company presence in USA. We will be updating on NUGN when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with NUGN.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in NUGN either long or short and we have not been compensated for this article.

Emerging Markets

Aclarion Inc (NASDAQ: ACON): A Breakthrough Partnership

Published

on

Aclarion, Inc. (NASDAQ: ACON) shares rocketed 157% Tuesday morning after their commercialization agreement with the London Clinic.

Aclarion, Inc. (NASDAQ: ACON) shares rocketed 157% Tuesday morning after their commercialization agreement with the London Clinic. The London Clinic is UK’s most renowned independent, private hospital, established 1932 with their Spine Clinic being the first specialist spinal unit based in England back in 1997.

“With a focus on providing the very best healthcare outcomes, The London Clinic is an ideal customer for Aclarion as the company works to deliver the Nociscan solution to physicians and patients around the world,” said John Sutcliffe MD, Neurosurgeon and Founder of London Spine Clinic. “The engagement with Aclarion will allow London Spine Clinic to continue offering the high-quality care our patients have come to expect. Patients need a careful assessment, diagnosis, and understanding of the different treatment options. Aclarion’s innovative Nociscan solution will enable us to objectively assess biomarkers associated with low back pain and enhance the precision of each diagnosis.”

More on Nociscan Technology

Aclarion, Inc.’s Nociscan Technology is an innovative medical solution that aims to revolutionize the diagnosis of disc-related conditions. They leverage biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain.

What’s exciting is its advantages over the current standard of care. It offers a non-invasive approach, ensuring patient comfort and safety. Given it’s non-invasive, that also means 0 pain with 0 radiation (typically associated with traditional discography). The best part is it can seamlessly integrate into standard lumbar MRI protocols, making it a convenient and efficient option for healthcare providers. 

To Discover the Inside Scoop on ACON, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

The procedure takes approximately 25-45 minutes, thoroughly evaluating spinal discs without compromising accuracy. Additionally, Nociscan technology offers significant cost savings, with a list price of $1,450, making it an affordable alternative to traditional discograms. Overall, Aclarion, Inc.’s technological advances represent a significant push forward in disc-related diagnostic techniques, prioritizing patient well-being, convenience, and affordability.

https://twitter.com/TigerLineTrades/status/1663527784143093762?s=20

Nociscan Study

They also recently completed a study that spanned two years and involved 78 patients at a single site. The success rate soared to an impressive 85% for patients whose treatment strategy aligned with the disks identified by Nociscan. This represented a remarkable 22% improvement over patients whose treatment strategy did not consider the insights provided by Nociscan.

Aclarion expressed confidence that the results of the trial demonstrate the potential of Nociscan to assist physicians in successfully treating DLBP. Dr. Matthew Gornet, orthopedic surgeon and lead author of the study, enthusiastically endorsed Nociscan, stating, “The two-year surgical outcomes of the clinical trial provide unequivocal evidence of its effectiveness, particularly with regards to the primary endpoint, the Oswestry Disability Index (ODI). I firmly believe that Nociscan has the potential to revolutionize the standard of care and accurately aid all physicians treating chronic low back pain.”

It is worth noting that although Nociscan was performed on all patients in the study, it was not part of the surgical decision-making process, as highlighted by the company.

Conclusion

The commercial agreement between Aclarion, Inc. and the prestigious London Clinic signifies a significant milestone for both parties, carrying the potential for global recognition, revenue growth, and scalability. By integrating Aclarion’s innovative Nociscan Technology, the London Clinic demonstrates its commitment to delivering cutting-edge healthcare to optimize patient well-being and enhance clinical outcomes. Furthermore, the partnership’s success holds the potential for scaling Nociscan Technology to other institutions and markets, propelling Aclarion, Inc. to become a global leader in non-invasive medical technologies while driving substantial revenue growth.

We will update you on ACON when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by PIRO from Pixabay

Continue Reading

Emerging Markets

Aemetis Inc. (NASDAQ: AMTX) Pioneers Renewable Fuel Market with EPA Approval

Published

on

Aemetis (NASDAQ: AMTX) shares surged 105% this week. The renewable natural gas and renewable fuels company received approval from the EPA.

Aemetis, Inc. (NASDAQ: AMTX) shares surged 105% this week. The renewable natural gas and renewable fuels company received approval from the U.S. EPA to generate renewable identification numbers (RINs) under the federal Renewable Fuel Standard. They have six dairy biogas digesters up and running, with a seventh one scheduled to start operating in June 2023.

Aemetis plans to generate multiple sources of revenue from its renewable natural gas. They will sell the gas to replace petroleum diesel in transportation, sell California Low Carbon Fuel Standard credits to fuel blenders who need to meet carbon reduction requirements in California, sell the RINs generated under the federal Renewable Fuel Standard, and benefit from production tax credits starting in 2025 under the Inflation Reduction Act.

They have completed constructing and operating six dairy digesters, a biogas pipeline spanning over 40 miles, a central facility to upgrade biogas to renewable natural gas, and a utility pipeline interconnection unit. The renewable natural gas is injected into the utility gas system and stored underground until Aemetis Biogas obtains carbon intensity (CI) pathway approvals from the California Air Resources Board (CARB) to sell credits under the California Low Carbon Fuel Standard.

They have already completed 90 days of renewable natural gas production and data collection required for the CARB approval process. While the final pathway is under review by CARB, Aemetis can use a temporary CI pathway with a value of -150, allowing them to start generating revenue in the third quarter of 2023.

To Discover the Inside Scoop on AMTX, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Andy Foster, the president of Aemetis Biogas Inc., expressed excitement about the approval of Aemetis Biogas for generating D3 RINs, as it marks a significant milestone towards generating full product revenue. He emphasized that the company’s investments since 2019 have directly reduced greenhouse gas pollution, improved air quality in Central Valley communities, and created jobs. Aemetis is committed to expanding their network of dairy digesters and producing more carbon-negative renewable natural gas to replace petroleum diesel.

The dairy digesters, pipeline project, and biogas-to-RNG facility funding includes grants from the California Department of Food and Agriculture and the California Energy Commission. Aemetis also closed a $25 million long-term financing deal with Greater Commercial Lending last fall, supported by a loan guarantee from the USDA. This project financing has a low fixed interest rate for the first five years and spans over 20 years.

Aemetis has plans to file applications for an additional $100 million of loans from the USDA’s REAP loan program. These funds will support the engineering, permitting, and construction of 31 more dairies. Each loan application will be limited to a maximum of $25 million and carry a 20-year repayment term.

https://twitter.com/Theweedfarmer/status/1658946668052504576?s=20

Where could Aemetis, Inc. (NASDAQ: AMTX) be in 5 years?

The company has an ambitious Five Year Plan to generate substantial revenue and reduce air and carbon pollution. The plan projects $2.0 billion in revenues, $496 million in net income, and $682 million in adjusted EBITDA by 2027, with strong compound annual growth rates. Aemetis aims to expand its operations by producing Renewable Natural Gas (RNG), Sustainable Aviation Fuel (SAF), Renewable Diesel fuel (RD), and other low-carbon products. The plan emphasizes the positive financial impact of the Inflation Reduction Act.

The plan highlights the financial benefits of the Inflation Reduction Act, which enables the transfer of tax credits and incentives related to production, projected to improve net income by $341 million in 2027.

The plan also focuses on revenue growth in all product lines, including expanding the dairy RNG business, constructing a renewable jet/diesel plant, implementing carbon sequestration, and improving energy efficiencies. 

The company has already achieved significant milestones, such as completing biogas pipeline construction, upgrading facilities for biogas-to-RNG production, and progressing in carbon sequestration and renewable jet/diesel plant development. The company has also secured a biodiesel purchase agreement in India and made strides in constructing a solar microgrid and implementing energy-efficient measures.

We will update you on AMTX when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Leopold Böttcher from Pixabay

Continue Reading

Emerging Markets

GSI Technology, Inc. (NASDAQ: GSIT): Pure AI Play Transforming Semiconductor Memory Solutions for Efficient AI Processing

Published

on

GSI Technology, Inc. (NASDAQ: GSIT) has witnessed a significant surge in its stock price, from $1.62 to $3.84, at the time of writing on Friday, May 12.

GSI Technology, Inc. (NASDAQ: GSIT) has witnessed a significant surge in its stock price, from $1.62 to $3.84, at the time of writing on Friday, May 12. This represents an impressive 137% increase; the volume has been off the hook. If you look at their historical chart, $GSIT had meager volume, sometimes as low as 300 shares traded in a day. If you do the math, that’s less than $500 worth of shares traded in a day – safe to say it was virtually illiquid.

So what happened, and what drove the stock to trade 50M shares with filings or news releases?

After an in-depth examination, GSI Technology, Inc. appears to have experienced a notable turning point in its market trajectory. The catalyst for this transformation was the company’s prominent feature on Fox News, triggering an exponential dissemination of information across various platforms. It is worth highlighting an intriguing phenomenon that tends to transpire in such circumstances: purchasing shares often induces a ripple effect, encouraging further buying activity.

With Fox News bringing the company into the spotlight and stimulating investor interest, a domino effect occurred among astute day traders who eagerly seized the opportunity to partake in this promising venture. Consequently, the trading volume for GSI Technology, Inc. skyrocketed to unprecedented levels, surpassing all previously recorded thresholds.

This surge in volume stands as a testament to the immense enthusiasm that enveloped the market as traders recognized the tremendous potential inherent in $GSIT. This collective enthusiasm resulted in an extraordinary demonstration of market engagement, reflecting a widespread acknowledgment of the company’s significance and the opportunities it presents.

https://twitter.com/SamanthaLaDuc/status/1657033207412293634?s=20

This development showcases the power of influential media coverage and underscores the intriguing dynamics that can arise when investor sentiment aligns with a compelling market narrative.

To Discover the Inside Scoop on GSIT, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Founded in 1995, GSI Technology Inc. has established itself as a prominent provider of semiconductor memory solutions. The company is focused on introducing new products that capitalize on its core strengths, which include radiation-hardened memory products for extreme environments and Gemini, an advanced processing unit (APU) designed to enhance performance in various artificial intelligence (AI) applications. Headquartered in Sunnyvale, California, GSI Technology operates sales offices in the Americas, Europe, and Asia.

GSI Technology is on the verge of reporting its earnings next week, and the company operates in the storage business, which supports the development of highly efficient AI chips. Traditionally, computing involves separate chips for storage and computation, necessitating frequent data exchange. This process incurs significant power consumption and presents scalability challenges.

To address these limitations, GSI Technology has developed a groundbreaking solution called In-memory processing. This innovation substantially reduces computation time from minutes to seconds, milliseconds, or even microseconds. Notably, it also significantly diminishes power consumption and overall cost of ownership. The key to this improvement lies in the massive parallel data processing offered by GSI’s technology, featuring two million-bit processors per chip compared to thousands found in standard graphic processing units (GPUs). Consequently, the system becomes more scalable, enabling efficient and accelerated AI processing.

By streamlining the computing process and integrating storage and computation on a single chip, GSI Technology aims to revolutionize AI processing. This approach offers notable benefits regarding power efficiency, computational speed, and scalability, making it an attractive solution for a wide range of AI applications.

In conclusion, GSI Technology, Inc. is poised to deliver innovative semiconductor memory solutions emphasizing AI chip development. The company aims to reduce computation time, power consumption, and total ownership cost through its In-memory processing technology while significantly improving scalability. With its upcoming earnings report, investors and industry observers will closely watch the company’s progress in the storage business and AI chip development.

We will update you on GSIT when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening with GSIT.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Gerd Altmann from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.